A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

← catalyst calendar

NCT06629779 · readout in 104 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

900estimated

Sites

236

Countries

Argentina, Brazil, Bulgaria +24

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-10-22

actual

When the study began enrolling

Primary completion

2026-12-02

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2028-11-30

estimated

The whole study's end, after follow-up

First posted

2024-10-08

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-14

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Metastatic Castration-Resistant Prostate Cancer

Interventions

Drug: PF-06821497 — also filed as Mevrometostat
Drug: Placebo
Drug: Enzalutamide — also filed as Xtandi

Primary outcome

what the primary-completion date above is the date OF

Radiographic Progression Free Survival (rPFS)

measured Randomization up to approximately 3 years

Publications

PMID 42108644 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed